
Tebentafusp, the first FDA-approved treatment option for patients with unresectable or metastatic uveal melanoma, may cause mild cytokine release syndrome, an expert explains.
Tebentafusp, the first FDA-approved treatment option for patients with unresectable or metastatic uveal melanoma, may cause mild cytokine release syndrome, an expert explains.
Published: February 14th 2022 | Updated: